阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

未开盘 01-30 16:00:00 EST

92.77

+0.18

+0.19%

盘后92.83

+0.06+0.06%

19:58 EST

最高93.51	最低92.46	成交量555.50万
今开93.03	昨收92.59	日振幅1.13%
总市值2,877亿	流通市值2,865亿	总股本31.01亿
成交额5.16亿	换手率0.18%	流通股本30.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":92.77,"timestamp":1769806800000,"preClose":92.59,"halted":0,"volume":5555024,"hourTrading":{"tag":"盘后","latestPrice":92.83,"preClose":92.77,"latestTime":"19:58 EST","volume":21303,"amount":1976337.8172,"timestamp":1769821126094,"change":0.06,"changeRate":0.000647,"amplitude":0.000647},"delay":0,"changeRate":0.0019440544335240588,"floatShares":3088302520,"shares":3101451738,"eps":3.009339,"marketStatus":"未开盘","change":0.18,"latestTime":"01-30 16:00:00 EST","open":93.03,"high":93.51,"low":92.46,"amount":516479322.974176,"amplitude":0.01134,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.009339,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770022800000},"marketStatusCode":0,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":92.59,"dividendRate":0.01687,"preHourTrading":{"tag":"盘前","latestPrice":93.05,"preClose":92.59,"latestTime":"09:29 EST","volume":118468,"amount":11031346.84624,"timestamp":1769783399098,"change":0.46,"changeRate":0.004968,"amplitude":0.010476},"postHourTrading":{"tag":"盘后","latestPrice":92.83,"preClose":92.77,"latestTime":"19:58 EST","volume":21303,"amount":1976337.8172,"timestamp":1769821126094,"change":0.06,"changeRate":0.000647,"amplitude":0.000647},"volumeRatio":0.8627176594043139,"impliedVol":0.3018,"impliedVolPercentile":0.7729},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2608833532","title":"中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608833532","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608833532?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:37","pubTimestamp":1769996220,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持石药集团“跑赢行业”评级，考虑对外授权持续兑现上调目标价9.1%到12港元。石药集团公告与阿斯利康签订研发合作与授权协议。中金主要观点如下：中国创新药授权出海再获里程碑式突破根据公告，石药集团及附属公司授权阿斯利康在全球范围内独家开发、生产和商业化8个创新长效多肽药物项目，阿斯利康将支付合计12亿美元预付款以及后续累计最高35亿/138亿美元的开发/销售里程碑款项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","AZN"],"gpt_icon":0},{"id":"2607604639","title":"阿斯利康全球CEO：中国在全球医药创新生态中不可或缺","url":"https://stock-news.laohu8.com/highlight/detail?id=2607604639","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607604639?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:16","pubTimestamp":1769779009,"startTime":"0","endTime":"0","summary":"中新社北京1月30日电(记者尹倩芸迟瀚宇)阿斯利康全球首席执行官苏博科(PascalSoriot)30日在北京接受中新社记者采访时表示，中国已成为全球医药创新生态中不可或缺的组成部分。阿斯利康近日宣布，计划于2030年前在中国投资逾1000亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303637319957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637319957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","LU0320765992.SGD","LU2462157665.USD","BK1574","BK1515","LU0109394709.USD","BK4585","LU0889565916.HKD","LU2236285917.USD","AZN","LU2456880835.USD","BK1161","BK4007","BK4588","BK4568","LU2417539215.USD","09939","LU1829250122.USD"],"gpt_icon":0},{"id":"2607905074","title":"石药集团(01093)与阿斯利康就创新长效多肽药物开发签订战略合作与授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2607905074","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607905074?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:11","pubTimestamp":1769731893,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议，以利用集团专有的缓释给药技术平台及多肽药物AI发现平台，开发创新长效多肽药物。同时，集团的多肽药物AI发现平台可以针对药物靶点快速设计及筛选候选分子，并可在药效、选择性与信号偏向性等维度进行系统优化。根据该协议的条款，集团将与阿斯利康在创新多肽分子的发现和长效递送产品的开发方面开展全面战略合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1008478684.HKD","HK0000165453.HKD","BK4585","LU2039709279.SGD","LU2417539215.USD","LU0109394709.USD","IE00BZ08YT58.USD","BK1191","AZN","BK4568","LU1328277881.USD","LU0889565916.HKD","LU2456880835.USD","LU0314109678.HKD","LU1993786604.SGD","LU0880133367.SGD","LU0140636845.USD","IE0008369823.USD","LU0315179316.USD","LU0072913022.USD","BK4007","LU0320765992.SGD","LU1829250122.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","LU1813983027.USD","LU1960683339.HKD","LU1226287875.USD","IE00BZ08YS42.EUR","LU2462157665.USD","BK1521","LU0501845795.SGD","LU1226287792.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","IE0008368742.USD","IE00B543WZ88.USD","LU1226287529.USD","LU1226288253.USD","LU1807302812.USD","SG9999004220.SGD","LU0326950275.SGD","LU2236285917.USD","BK4588","BK1515","LU0067412154.USD","LU1951186391.HKD","LU1226288170.HKD","01093","LU1152091168.USD"],"gpt_icon":0},{"id":"2607082557","title":"【财闻联播】阿斯利康：将在华投资逾1000亿元！多只黄金股提示风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2607082557","media":"券商中国","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607082557?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:11","pubTimestamp":1769688660,"startTime":"0","endTime":"0","summary":"报告期内，财富管理、资产管理、投资交易等业务收入实现同比增长，公司整体经营业绩显著提升。若该基金2026年2月2日二级市场交易价格溢价幅度未有效回落，基金有权通过向深圳证券交易所申请盘中临时停牌、延长停牌时间等措施，向市场警示风险，具体以届时公告为准。阿斯利康将于2030年前在华投资逾1000亿元　　阿斯利康今日宣布，计划于2030年前在中国投资逾1000亿元人民币，以扩大在药品生产与研发领域的布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-29/doc-inhiyrwi1005758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1829250122.USD","BK4568","LU2456880835.USD","BK4585","LU0109394709.USD","BK4588","LU2462157665.USD","LU2417539215.USD","AZN","BK4007","LU0889565916.HKD","159562","LU2236285917.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2607088305","title":"阿斯利康宣布到2030年将在中国投资150亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607088305","media":"第一财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607088305?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:59","pubTimestamp":1769680778,"startTime":"0","endTime":"0","summary":"【阿斯利康宣布到2030年将在中国投资150亿美元】英国制药公司阿斯利康宣布，到2030年将在中国投资150亿美元，用于扩大研发和生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601293635388560.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635388560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU0320765992.SGD","LU0889565916.HKD","BK4588","LU1829250122.USD","BK4568","LU0109394709.USD","LU2456880835.USD","AZN","LU2417539215.USD","LU2462157665.USD","BK4007","LU2236285917.USD"],"gpt_icon":0},{"id":"2607700539","title":"英国首相斯塔默：阿斯利康在中国的投资将帮助该公司持续增长，并支持数以千计的英国就业岗位。","url":"https://stock-news.laohu8.com/highlight/detail?id=2607700539","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607700539?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:50","pubTimestamp":1769680249,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","LU2456880835.USD","BK4568","AZN","LU2417539215.USD","LU2236285917.USD","LU2462157665.USD","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","BK4007","LU1829250122.USD","BK4588"],"gpt_icon":0},{"id":"2607700532","title":"阿斯利康：到2030年，将在中国投资150亿美元，以扩大研发和制造业务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2607700532","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607700532?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:50","pubTimestamp":1769680218,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0889565916.HKD","LU2456880835.USD","BK4585","AZN","LU2462157665.USD","LU2417539215.USD","BK4007","BK4588","BK4568","LU0109394709.USD","LU0320765992.SGD","LU1829250122.USD","LU2236285917.USD"],"gpt_icon":0},{"id":"2606088432","title":"花旗：予阿斯利康“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2606088432","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606088432?lang=zh_cn&edition=full","pubTime":"2026-01-27 14:26","pubTimestamp":1769495173,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2462157665.USD","LU1244550221.USD","LU0889565916.HKD","LU1244550494.USD","LU0320765992.SGD","BK4007","LU0109394709.USD","LU2360032135.SGD","LU1791807156.HKD","LU1366192091.USD","LU0170899867.USD","LU1668664300.SGD","LU2236285917.USD","LU1201861249.SGD","LU0052756011.USD","LU0072461881.USD","LU0980610538.SGD","AZN","LU0130517989.USD","BK4559","BK4534","LU0648001328.SGD","BK4568","IE00BSNM7G36.USD","LU0162691827.USD","LU1244550577.SGD","LU1162221912.USD","BK4585","LU0477156953.USD","LU2125154778.USD","LU0106831901.USD","LU0310800965.SGD","LU0098860793.USD","BK4566","LU2417539215.USD","LU2125154935.USD","LU2456880835.USD","LU1267930227.SGD","BK4504","LU1829250122.USD","LU0130102774.USD","BK4207","BK4588","LU0128525689.USD","LU0320765646.SGD"],"gpt_icon":0},{"id":"2606208876","title":"阿斯利康告别纳斯达克，统一全球上市平台，地缘政策与价值重估的双重考量","url":"https://stock-news.laohu8.com/highlight/detail?id=2606208876","media":"华夏时报网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606208876?lang=zh_cn&edition=full","pubTime":"2026-01-27 14:22","pubTimestamp":1769494936,"startTime":"0","endTime":"0","summary":"2026年1月20日，英国制药巨头阿斯利康宣布，将自愿从纳斯达克退市其美国存托凭证及债务证券，相关调整将于1月30日收盘后正式生效。从2月2日起，这家全球领先的生物制药企业将在纽约证券交易所开始交易其普通股及债券，股票代码仍为“AZN”。这不是一次简单的交易所转移，而是阿斯利康构建“统一上市结构”的关键一步。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273632092534.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273632092534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["USJW.SI","PSQ","TQQQ","LU2456880835.USD","BK4568","QQQE","GPIQ","LU0320765992.SGD","USAW.SI","QID","QYLD","LU0889565916.HKD","NVIW.SI","NQmain","TSYW.SI","LU0109394709.USD","QQQJ","LU2462157665.USD","BK1147","BK4007","QLD","BK4585","LU2236285917.USD","QQQY","MNQmain","QYLG","JEPQ","SQQQ","BK4588","AZN","LU1829250122.USD","LU2417539215.USD"],"gpt_icon":1},{"id":"2606213404","title":"阿斯利康中国(AZN)：舒立瑞在华获批用于治疗6岁及以上儿童难治性全身型重症肌无力患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2606213404","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606213404?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:12","pubTimestamp":1769418767,"startTime":"0","endTime":"0","summary":"金吾财讯 |据阿斯利康中国(AZN)消息，中国国家药品监督管理局已正式批准舒立瑞®（英文商品名： Soliris®，通用名：依库珠单抗注射液），适应症扩展至用于治疗6岁及以上抗乙酰胆碱受体（AChR）抗体阳性的难治性全身型重症肌无力（gMG）儿童患者。gMG是一种罕见的、致残性、慢性自身免疫性神经肌肉疾病，可导致肌肉功能丧失和严重衰弱。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"296558","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","AZN","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","LU2236285917.USD","BK4007","LU2417539215.USD","LU1829250122.USD","BK4585","LU2456880835.USD","LU2462157665.USD","BK4588"],"gpt_icon":0},{"id":"2605429045","title":"第一三共/阿斯利康(AZN.US)“德曲妥珠单抗”在华获批治疗HER2阳性胃癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2605429045","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605429045?lang=zh_cn&edition=full","pubTime":"2026-01-23 14:45","pubTimestamp":1769150736,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月22日，第一三共/阿斯利康共同宣布，注射用德曲妥珠单抗正式获得中国国家药品监督管理局批准，单药用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。据悉，该适应症是德曲妥珠单抗在华获批的第六个适应症，也是HER2阳性胃癌相关的第二个适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU0320765992.SGD","LU0109394709.USD","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","BK4588","BK4585","LU2417539215.USD","LU0889565916.HKD","AZN","BK4568","LU2236285917.USD"],"gpt_icon":0},{"id":"2605290194","title":"阿斯利康(AZN.US)宣布PD-L1单抗在华获批新适应症 针对子宫内膜癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2605290194","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605290194?lang=zh_cn&edition=full","pubTime":"2026-01-23 14:42","pubTimestamp":1769150545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月22日，阿斯利康宣布，英飞凡已获中国国家药品监督管理局批准，与卡铂和紫杉醇联合用于错配修复缺陷的原发晚期或复发性子宫内膜癌成人患者的一线治疗，随后以本品单药维持治疗。截至目前该药已在美国获批 10 项适应症，在欧盟获批 11 项适应症，在国内获批 7 项。安全性方面，度伐利尤单抗联合化疗方案的总体安全性和耐受性良好，并且与此前临床试验结果总体一致，没有出现新的安全信号。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2456880835.USD","BK4588","LU1169590202.USD","LU0889565916.HKD","LU1829250122.USD","LU1169589451.USD","PD","BK4585","BK4568","AZN","BK4023","LU0109394709.USD","LU2236285917.USD","LU2417539215.USD","LU0320765992.SGD","LU2462157665.USD","BK4007"],"gpt_icon":0},{"id":"2605495703","title":"优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495703?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1894683348.USD","LU2237443622.USD","LU1221951046.USD","BK4612","LU2247934214.USD","CSCO","LU0234572021.USD","LU1244550494.USD","LU2506952097.USD","LU0320765992.SGD","BK4588","BK4231","LU0109394709.USD","LU2237443382.USD","LU1571399168.USD","LU1880398554.USD","LU1066051498.USD","BK4579","LU2237443895.HKD","LU1196500208.SGD","AZN","LU1929549753.HKD","LU0868494617.USD","BK4560","LU2506951958.HKD","ORR","LU2237443549.SGD","SG9999015978.USD","SG9999015945.SGD","LU1244550577.SGD","LU1066053197.SGD","PFS","BK4585","ADC","BK4097","LU1046421795.USD","IE000M9KFDE8.USD","BK4527","LU2506951875.HKD","LU2462157665.USD","LU1221951129.SGD","SG9999001440.SGD","BK4195","LU0792757196.USD","LU2417539215.USD","OS","BK4080","LU1880398471.USD","IE00BFMHRM44.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2604167035","title":"阿斯利康将从纳斯达克转板到纽交所直接上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2604167035","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604167035?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:33","pubTimestamp":1768894380,"startTime":"0","endTime":"0","summary":"英国制药巨头阿斯利康公司周二表示，将从纳斯达克交易所摘除其美国存托股票和债券，并于 2026 年 1 月 30 日股市收盘后完成其普通股和债券在纽约证券交易所的直接上市。　　这一举措是经阿斯利康股东批准的一项计划的一部分，旨在统一公司的股票上市结构，使投资者能够在伦敦证券交易所、纳斯达克斯德哥尔摩交易所和纽约证券交易所之间交易其普通股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-20/doc-inhhxvez7499886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["JEPQ","GPIQ","LU2462157665.USD","BK4007","QQQM","QQQE","MNQmain","BK1147","LU0889565916.HKD","BK4585","LU2456880835.USD","TQQQ","QQQ","QYLD","SQQQ","BK4588","LU0109394709.USD","USAW.SI","LU0320765992.SGD","QLD","QQQY","AZN","QYLG","PSQ","QID","QQQJ","LU1829250122.USD","LU2236285917.USD","NVIW.SI","LU2417539215.USD","BK4568","USJW.SI","TSYW.SI"],"gpt_icon":0},{"id":"2604216257","title":"阿斯利康：将在纽约证券交易所完成直接上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2604216257","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604216257?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:07","pubTimestamp":1768892829,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0109394709.USD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","LU2236285917.USD","LU2417539215.USD","BK4568","LU2456880835.USD","AZN","LU0889565916.HKD","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"2604183102","title":"阿斯利康收购西比曼生物GPC3装甲型CAR-T疗法在中国的剩余权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2604183102","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604183102?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:20","pubTimestamp":1768807256,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","LU0109394709.USD","BK4230","BK4588","BK4585","CAR","AZN","LU2417539215.USD","BK4022","BK4568","LU0320765992.SGD","LU0889565916.HKD","LU2236285917.USD","BK4007"],"gpt_icon":0},{"id":"2603162087","title":"AI将重构创新药研发格局！礼来、阿斯利康等密集宣布新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=2603162087","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603162087?lang=zh_cn&edition=full","pubTime":"2026-01-15 11:38","pubTimestamp":1768448291,"startTime":"0","endTime":"0","summary":"近期，包括礼来、阿斯利康等头部药企也再宣布AI制药的布局动态。如阿斯利康近日宣布收购生物医学人工智能公司Modella AI，双方将扩大现有合作，共同推进多模态AI基础模型和AI代理在阿斯利康全球肿瘤产品组合中的应用。除了阿斯利康，近日礼来和英伟达宣布，将成立一家专注于药物开发的联合创新 AI 实验室。头部药企的密集布局，背后是AI技术为创新药研发带来的价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115114832a71cb399&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115114832a71cb399&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015945.SGD","LU0323591593.USD","IE0009355771.USD","LU1989772923.USD","LU1629891620.HKD","IE00B2B36J28.USD","SG9999014880.SGD","LU0114720955.EUR","NVDX","LU0390134368.USD","BK4534","LU2361044865.SGD","LU2463028550.USD","LU0471298694.HKD","LU0320765992.SGD","IE00B7KXQ091.USD","LU2097344357.USD","LU2077746001.SGD","LU0234572021.USD","LU0444973449.USD","IE00B1BXHZ80.USD","SG9999014559.SGD","LU2552382058.USD","IE00BFSS7M15.SGD","LU0683600562.USD","LU0466842654.USD","LU2491050071.SGD","LU1084165304.USD","IE00BJJMRZ35.SGD","IE00BHPRN162.USD","SG9999018857.SGD","LU1116320737.USD","SG9999000418.SGD","HK0000320223.HKD","IE0034235188.USD","IE0004445239.USD","LU2272731782.SGD","LU2264538146.SGD","LU0310800379.SGD","LU2087625088.SGD","LU2237438978.USD","LU1093756325.SGD","LU2089283258.USD","LU2750360997.AUD","LU2237443382.USD","LU0385154629.USD","LU0820561909.HKD","LU2471134796.USD","LU1066051498.USD","LU0345769128.USD","LU1551013425.SGD","LU1261432733.SGD","IE00BJJMRX11.SGD","LU2237443465.HKD","LU0057025933.USD","LU0070217475.USD","LU0354030511.USD","LU1244550494.USD","LU0788109477.HKD","LU2452424414.USD","LU0061474960.USD","SG9999002224.SGD","BK4548","LU0211328371.USD","LU0053666078.USD","LU1778281490.HKD","LU0154236417.USD","LU1923623000.USD","IE00BK4W5L77.USD","LU0719512351.SGD","LU2089984988.USD","LU0965509010.AUD","LU1623119135.USD","LU2108987350.USD","LU0476273544.USD","LU0964807845.USD","LU1244550577.SGD","LU0109392836.USD","LU0868494617.USD","LU2054465674.USD","IE0034235303.USD","LU2237957811.SGD","LU1803068979.SGD","LU0979878070.USD","LU2247934214.USD","LU2092937148.SGD","LU2360107168.USD","LU0274383776.USD","LU2413666699.HKD","LU1548497426.USD","LU2458330169.SGD","LU1267930730.SGD","IE00BKPKM429.USD","LU0289739699.SGD","LU2860962120.EUR","LU1868836914.USD","LU1992135399.USD","LU1935043536.SGD","IE00BN29S564.USD","BK4554","LU0823414551.USD","LU2360106780.USD","LU2461242641.AUD","LU0820562030.AUD","LU0942090050.USD","LU0082616367.USD","LU1934455863.HKD","BK4614","LU1951198990.SGD","SGXZ51526630.SGD","LU2462157665.USD","LU1839511570.USD","LU0061475181.USD","LU2290526834.HKD","BK4503","LU2430703251.USD","LU2746668974.SGD","LU0234570918.USD","NVD2.UK","NVIW.SI","LU0106261372.USD","BK4007","LU0308772762.SGD","LU2473716301.USD","LU2403377893.USD","LU0354030438.USD","LU2249611893.SGD","LU0081259029.USD","LU1066053197.SGD","LU2097344431.USD","IE00BDRTCR15.USD","LU0689626769.HKD","LU1267930573.SGD","LU1037948541.HKD","IE00B19Z8W00.USD","LU0310799852.SGD","LU1323610961.USD","SG9999014575.USD","SG9999015358.SGD","LU1023059063.AUD","LU2357125470.USD","LU0203202063.USD","LU0689472784.USD","LU0157215616.USD","IE00B775H168.HKD","LU1035775433.USD","BK4568","LU0889565916.HKD","LU0943347566.SGD","LU0210533765.USD","LU2063271972.USD","LU2381873111.SGD","LU2125909916.SGD","LU1804176565.USD","LU2322448791.USD","BK4587","SG9999004303.SGD","LU1974910355.USD","LU2430703178.SGD","HK0000306685.HKD","LU0348723411.USD","LU1935042488.USD","LU1066051811.HKD","SG9999001176.USD","LU2420271590.USD","LU0289960550.SGD","IE00BJJMRY28.SGD","LU0823421416.USD","BK4608","LU0170899867.USD","HK0000320264.USD","IE0009356076.USD","LU0069063385.USD","LU2361045086.USD","LU0256863902.USD","IE00BMPRXN33.USD","LU1923622291.USD","LU0006306889.USD","NVDA","LU0642271901.SGD","LU0094547139.USD","LU0965509283.SGD","LU1861220033.SGD","LU1699723380.USD","LU0077335932.USD","LU0472753341.HKD","LU0882574139.USD","LU1267930490.SGD","LU2023250330.USD","LU2250418816.HKD","LU2896262040.SGD","LU1242518931.SGD","LU2272731865.HKD","BK4551","IE0003U64NQ7.SGD","LU1815336760.USD","LU2294711713.HKD","IE00B4YYXB79.USD","LU2191332357.HKD","LU0029864427.USD","LU1232071149.USD","IE00BMPRXR70.SGD","LU2065171402.SGD","LU2505996681.GBP","SG9999018865.SGD","LU1983299246.USD","LU2433249047.HKD","LU2552382215.SGD","LU0210536198.USD","LU0985320562.USD","IE00BJT1NW94.SGD","LU2505996509.AUD","IE00B3M56506.USD","LU2265009873.SGD","LU2236285917.USD","LU1093756168.USD","LU1829250122.USD","NVDS.UK","BK4533","LU2456880835.USD","IE0005OL40V9.USD","SGXZ23171101.USD","IE00BKVL7J92.USD","LU1291159041.SGD","IE00B19Z8X17.USD","LU2272731600.USD","LU0187121727.USD","SNVD.UK","LU0353189763.USD","LU1934455277.USD","LU2023250504.SGD","LU1815333072.USD","LU0347712357.USD","LU2357305700.SGD","LU1145028129.USD","LU1989764664.SGD","IE0004091025.USD","LU0266013472.USD","BK4598","LU2092627202.USD","LU2023251221.USD","LU0079474960.USD","LU0158827948.USD","LU2430703095.HKD","SGXZ99366536.SGD","LU0820561818.USD","LU0289739343.SGD","LU0345768153.USD","LU0787776722.HKD","LU1069344957.HKD","LU2168563687.JPY","LU1868836757.USD","IE00B19Z9505.USD","IE00BFTCPJ56.SGD","LU0225283273.USD","LU1992135472.HKD","LU1720051108.HKD","LU0198837287.USD","LU2125909247.SGD","LU1057294990.SGD","HK0000914686.HKD","LU0511384066.AUD","LU2112291526.USD","LU2471134523.USD","GB00BDT5M118.USD","IE00BJTD4N35.SGD","LU1988902786.USD","NVDG","LU1551013342.USD","LU1989772840.SGD","LU1983260115.SGD","BK4549","IE00BJTD4V19.USD","LU1951200564.SGD","LU0471298777.SGD","BK4612","LU2324357040.USD","LU2237443622.USD","LU1935042215.USD","SGXZ81514606.USD","SG9999001176.SGD","LU0097036916.USD","SG9999014898.SGD","LU2125909593.SGD","LU2125154935.USD","LU0823414478.USD","LU0109394709.USD","IE0004445015.USD","LU0432979614.USD","LU1127390331.HKD","LU1791710400.SGD","LU2168564222.USD","LU0342679015.USD","NVII","LU2168564149.EUR","LU1791710582.SGD","NVD","LU0882574055.USD","LU0861579265.USD","LU1066051225.USD","LU1571399168.USD","SG9999014542.SGD","LU2125909759.SGD","IE00B4JS1V06.HKD","LU2237443978.SGD","LU2089985449.USD","BK4527","LU2592432038.USD","LU2471134879.HKD","LU1989764748.USD","BK4516","LU1242518857.USD","LU0823421333.USD","LU1917777945.USD","LU0122379950.USD","LU2487616109.SGD","LU2746668461.USD","IE00B3SWFQ91.USD","LU2213496289.HKD","LU2106854487.HKD","LU2326559502.SGD","LU0823434740.USD","LU2168564065.EUR","LU0528227936.USD","LU2543165471.USD","SG9999015952.SGD","LU0672654240.SGD","LU0080751232.USD","LU0238689110.USD","LU0345770308.USD","LU0345769631.USD","SG9999015978.USD","LU2065171311.SGD","LU0175139822.USD","BK4141","LU1674673428.USD","LU1868837300.USD","LU0128525929.USD","LU0215105999.USD","HK0000914660.USD","SG9999015341.SGD","IE00BZ199S13.USD","LU0096362180.USD","SG9999014567.USD","BK4567","LU1923622614.USD","LU1868836591.USD","LU0127658192.USD","SG9999014914.USD","IE00BWXC8680.SGD","LU1642822529.SGD","LU2237443549.SGD","LU2211815571.USD","BK4581","LU1496350171.SGD","LU0823416689.USD","LU0957791311.USD","LU2242650005.HKD","LU0210528500.USD","LU2491050154.USD","LU2271345857.HKD","LU1119994496.HKD","LLY","LU2361044949.HKD","LU0417517546.SGD","SG9999001424.SGD","LU2028103732.USD","LU0124676726.USD","BK4579","LU1914381329.SGD","LU1721428933.USD","LU0868494708.USD","LU1496350502.SGD","LU0320765059.SGD","LU0072462426.USD","LU1712237335.SGD","LU0724617625.USD","LU1280957306.USD","LU2065170008.USD","LU2602419157.SGD","LU1366192091.USD","LU2458330243.SGD","LU2168564495.EUR","LU0957808578.USD","NVDS","LU0256863811.USD","SG9999014906.USD","LU0708994859.HKD","LU2417539215.USD","SG9999015986.USD","LU0708995401.HKD","LU0965508806.USD","IE0002141913.USD","SG9999017495.SGD","LU0494093205.USD","LU1116320901.HKD","LU1720051017.SGD","LU0061474705.USD","LU2322448957.HKD","SG9999013999.USD","SGXZ57979304.SGD","LU1691799644.USD","IE0034235295.USD","IE00BJLML261.HKD","BK4529","SGXZ31699556.SGD","LU2089284900.SGD","BK4532","LU2360032135.SGD","LU1316542783.SGD","NVDY","LU2552382132.HKD","LU0456855351.SGD","LU0056508442.USD","LU1814569148.SGD","IE0001KFT4U8.USD","IE00BMPRXQ63.HKD","NVD3.UK","LU0265550359.USD","LU0109391861.USD","IE00BQXX3D17.EUR","LU0289961442.SGD","BK4605","LU2111349929.HKD","LU2756315664.SGD","IE00BK4W5M84.HKD","LU2237957902.USD","IE000YTNTUN2.SGD","LU0158827781.USD","2NVD.UK","IE00BDCRKT87.USD","LU1435385759.SGD","LU1821325948.USD","BK4585","LU1852331112.SGD","LU2471134952.CNY","LU0889565833.HKD","IE00BD6J9T35.USD","LU0267386448.USD","LU0058720904.USD","LU2413666426.HKD","LU2286300806.USD","LU1861215975.USD","LU0096364046.USD","LU2756315318.SGD","LU2065169927.USD","LU1037948897.HKD","IE00BQXX3C00.GBP","IE00B4R5TH58.HKD","BK4550","LU1061106388.HKD","IE00B1XK9C88.USD","LU0640476718.USD","IE000KEQY171.SGD","SG9999002232.USD","NVDW","IE000W1ABFV2.USD","LU0211327993.USD","LU2491049909.HKD","NVDU","LU1935042991.SGD","LU0265550946.USD","BK4543","IE00BZ1G4Q59.USD","LU2242649171.HKD","LU1674673691.USD","LU1861127337.USD","LU1429558221.USD","LU2125154778.USD","LU0786609619.USD","IE00B5949003.HKD","LU2468319806.SGD","LU0203201768.USD","HK0000306701.USD","LU0048584097.USD","LU1868837136.USD","IE00BKDWB100.SGD","BK4588","IE0004086264.USD","LU1934455194.USD","LU1935043023.USD","IE00BYXW3230.USD","LU2244417387.USD","LU1064131342.USD","IE000ITXATA3.USD","LU0557290698.USD","LU1718418525.SGD","IE00BQXX3F31.USD","LU1989771016.USD","LU0316494557.USD","LU2237443895.HKD","LU0276348264.USD","AZN","LU0353189680.USD","LU0107464264.USD","LU0965509101.SGD","BK4592","LU2506951792.HKD","LU2083900584.USD","LU1366333091.USD","LU2360106947.USD","LU0823434583.USD","LU2750360641.GBP","LU1633808545.USD","LU2087621335.USD","3NVD.UK","BK4599","IE0009G5SDU7.USD","LU0251132253.USD","LU0345768740.USD","LU0444971666.USD","NVDQ","LU2931357623.SGD","DIPS","LU1244550221.USD","LU0345770993.USD","IE00BFSS8Q28.SGD","NVDD"],"gpt_icon":1},{"id":"2603697640","title":"阿斯利康(AZN)收购Modella AI，将加速肿瘤药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2603697640","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603697640?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:55","pubTimestamp":1768388101,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)收购生物医学人工智能公司Modella AI，双方将扩大现有合作，共同推进多模态AI基础模型和AI代理在阿斯利康全球肿瘤产品组合中的应用。收购完成后，Modella AI的生成式和智能体AI平台将整合到阿斯利康的肿瘤药物研发体系中，助力加速临床开发。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NWE0NDM0MDU5NDk3NzI5.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWE0NDM0MDU5NDk3NzI5.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"296249","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2236285917.USD","BK4588","LU2417539215.USD","LU0109394709.USD","LU2456880835.USD","BK4007","AZN","LU0320765992.SGD","LU1829250122.USD","BK4568","LU2462157665.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2603439618","title":"阿斯利康AZD0486启动III期临床 适应症为新诊断的老年或不适合化疗的大B细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2603439618","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603439618?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:03","pubTimestamp":1768384980,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，AstraZeneca AB/阿斯利康全球研发（中国）有限公司/AstraZeneca Nijmegen B.V.的AZD0486在新诊断为大B细胞淋巴瘤的老年或不适合化疗的受试者中的多中心、开放性、随机III期临床试验已启动。本次试验药AZD0486的剂型、用法用量信息未公示。AZD0486为生物制品，适应症为新诊断的老年或不适合化疗的大B细胞淋巴瘤。大B细胞淋巴瘤是常见的非霍奇金淋巴瘤亚型，进展快，老年或不耐受化疗患者预后较差，需更安全有效的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114190129a4c2fc89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114190129a4c2fc89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2462157665.USD","LU1829250122.USD","LU0320765992.SGD","LU2456880835.USD","LU0109394709.USD","LU2236285917.USD","AZN","LU2417539215.USD","BK4568","III","BK4134","BK4585","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2603662033","title":"2026年肿瘤药物研发将驶上 “快车道” ，开年药企合作/并购密集","url":"https://stock-news.laohu8.com/highlight/detail?id=2603662033","media":"制药网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603662033?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:52","pubTimestamp":1768373563,"startTime":"0","endTime":"0","summary":"此次收购，阿斯利康旨在借助Modella AI在人工智能领域的技术优势，进一步强化其在肿瘤药物研发方面的能力。目前，荣昌生物正在中国开展RC148单药及联合疗法治疗多种晚期恶性实体瘤患者的临床研究。2026年，医药企业在肿瘤药物领域的合作与并购的浪潮预计将持续。众多企业将通过技术突破、临床提速、资源整合，推动肿瘤药物研发进入 “快车道”，在此背景下，AI药物、下一代细胞疗法、新型偶联药物等或将有望实现临床与商业化双突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114145643a4c2036c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114145643a4c2036c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","03696","BK1574","BK1583","LU1969619763.USD","LU2328871848.SGD","BK1161","09995"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0019},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.1258},{"period":"6month","weight":0.2545},{"period":"1year","weight":0.3022},{"period":"ytd","weight":0.0091}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018335},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}